The world of scientific research is dense and vast not unlike a thick jungle. There are so many sources of information coming from multiple science channels that it has become hard to navigate through it all. We created the Innovation Hub so that those of you traveling into the jungle of drug discovery can explore it with ease and find the latest and greatest innovations.

Full access to the Innovation Hub is limited to our current users, but each month we share a sampling of its content through these monthly blog posts. You can see our top 8 picks for this month straight from the Innovation Hub below:

3D Triculture Breast Cancer Model
Use tricultures of breast cancer cell lines, hMSCs, and endothelial tubules for evaluating breast cancer progression.

In this model, three different cell types are cultured together: breast cancer cell line, human umbilical vein endothelial cells, and human adipose-derived mesenchymal stem cells. The triculture model closely mimics the extracellular environment, cellular architecture, and behavior of actual tumors.

LRRK2 Cell Lines  – an in vitro model for Parkinson’s disease
Use genomically altered cell lines to develop therapies aimed at correcting or lowering deleterious LRRK2 signaling.

These cell lines overexpress mutant versions (linked to Parkinson’s disease) of full-length LRRK2. This tool will help researchers better understand Parkinson’s disease mechanisms and develop new therapies.

Artery-on-a-chip platform
Assess small blood vessels under close-to in vivo conditions.

This platform loads and immobilizes small arteries within a microfluidic channel, where they can be maintained and analyzed under near-in vivo physiological conditions.

CRISPR-Cpf1 System
Use the CRISPR-Cas9 alternative for mammalian genome editing.

This new DNA-editing tool works analogously to CRISPR/Cas9, which has revolutionized research in genome editing. CRISPR/Cpf1 is potentially better than CRISPR/Cas9 as Cpf1 is smaller and simpler than Cas9, which simplifies delivery to the cells whose genes need modifying.

BioFab® Platform
Manufacture long-length DNA constructs simultaneously in a single reaction.

This DNA synthesis platform will help researchers translate vast information from genome sequencing projects into quickly actionable results and reduce the massive discrepancy between the annual global capacity for “reading” DNA (sequencing) and “writing” DNA (synthesis).

Regenova® 3D Bio Printing
Fabricate 3D tissue from primary cells using the Regenova 3D Bio Printer.

This 3D Bio Printer facilitates the fabrication of 3D cellular structures by placing cellular spheroids in fine needle arrays (“Kenzan method”) according to pre-designed 3D data.

Single Fluorescent Protein-based Biosensors
Detect Gi, Gs, and Gq-coupled pathways of GPCR signaling.

This new Gi assay for live primary cells uses a constitutively active mutant Gs to increase cAMP levels instead of disrupting the cell with Forskolin or IBMX.

Bacterial Cytological Profiling (BCP) Platform
Determine the mode of action for newly discovered antimicrobial compounds.

The BCP platform can be used to rapidly identify and study the mechanism of action (MOA) for compounds active against Gram positive or Gram negative bacteria.

Let’s keep the conversation going — use hashtag #sparkofinnovation to join the conversation on Twitter and Facebook!

Posted 9:27 pm,

Every month Assay Depot’s platform gets more innovative with hundreds of new tools, technologies, and services. The platform users gain on-demand access to recently commercialized  innovations  ranging from exciting optogenetic tools to freshly developed 3D culture systems.  The innovations we select come from a wide range of sources such as conferences, technical papers, interviews from […]

Read More...
Posted 10:31 am,

What are Public-Private Partnerships for Drug Discovery? In recent decades, the proliferation of world-wide epidemics and health emergencies (such as HIV, MERS, Ebola, and most recently Zika) has inspired efforts to improve the pace of drug discovery through large-scale collaborations. So-called Public-Private Partnerships (PPPs) have been implemented in Europe (Innovative Medicines Initiative), in the United […]

Read More...
Posted 4:42 pm,

Let’s keep the conversation going — use hashtag #sparkofinnovation to join the conversation on Twitter and Facebook!

Read More...
Posted 9:58 am,

Posted 3:58 am,

Arthur Clarke once famously said that “Any sufficiently advanced technology is indistinguishable from magic.”  Below we’ve listed eight advanced technologies that, while not magic, represent the most cutting-edge science available today.

Read More...
Posted 6:07 am,

In the world of drug discovery, pharmaceutical companies face a very sobering statistic – more than 90% of the drugs that reach clinical testing will fail. This high failure rate is not only a major financial concern for the pharma industry, but it also negatively affects the millions of patients that are sick and desperately […]

Read More...
Posted 8:01 am,

From the desk of Chris Lipinski, PhD I’ve been thinking a lot lately about how to optimize for ligand affinity. Of course, this is a central theme of all drug discovery projects. At its core is the question of how physical and chemical relationships guide the interplay between the ligand, the protein target, and the […]

Read More...
Posted 1:40 pm,

Anyone who has taken a general laboratory class knows that the lab manual has multiple protocols that one follows in order to complete each week’s assignment. However, while the class laboratory protocol has been thoroughly tested, academic and industry protocols are often changed and improved as new information is gleaned from previous experiments. A new […]

Read More...
Posted 11:09 am,

Drug discovery, ever a challenge, can be likened to a tall structure. The upper stories rely on the stability of the floors below it, and a solid foundation is a must. No lofty heights will be reached when the base is not secure. And so, it is not a surprise that a drug discovery project […]

Read More...
Posted 10:36 am,